AlloVir Statistics
Total Valuation
AlloVir has a market cap or net worth of $89.70 million. The enterprise value is -$33.04 million.
| Market Cap | 89.70M |
| Enterprise Value | -33.04M |
Important Dates
The last earnings date was Monday, May 13, 2024, before market open.
| Earnings Date | May 13, 2024 |
| Ex-Dividend Date | n/a |
Share Statistics
AlloVir has 115.00 million shares outstanding. The number of shares has increased by 22.92% in one year.
| Shares Outstanding | 115.00M |
| Shares Change (YoY) | +22.92% |
| Shares Change (QoQ) | +0.45% |
| Owned by Insiders (%) | 49.25% |
| Owned by Institutions (%) | 43.08% |
| Float | 39.37M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| Forward PS | n/a |
| PB Ratio | 0.74 |
| P/FCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 18.48, with a Debt / Equity ratio of 0.15.
| Current Ratio | 18.48 |
| Quick Ratio | n/a |
| Debt / Equity | 0.15 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | n/a |
Financial Efficiency
Return on equity (ROE) is -104.00% and return on invested capital (ROIC) is -136.16%.
| Return on Equity (ROE) | -104.00% |
| Return on Assets (ROA) | -82.90% |
| Return on Capital (ROIC) | -136.16% |
| Revenue Per Employee | n/a |
| Profits Per Employee | -$1.60M |
| Employee Count | 112 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
| Income Tax | -126,000 |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -81.32% in the last 52 weeks. The beta is 0.78, so AlloVir's price volatility has been lower than the market average.
| Beta (1Y) | 0.78 |
| 52-Week Price Change | -81.32% |
| 50-Day Moving Average | 0.77 |
| 200-Day Moving Average | 1.46 |
| Relative Strength Index (RSI) | 49.98 |
| Average Volume (30 Days) | 479,906 |
Short Selling Information
The latest short interest is 6.72 million, so 5.85% of the outstanding shares have been sold short.
| Short Interest | 6.72M |
| Short Previous Month | 6.40M |
| Short % of Shares Out | 5.85% |
| Short % of Float | 17.08% |
| Short Ratio (days to cover) | 13.35 |
Income Statement
| Revenue | n/a |
| Gross Profit | n/a |
| Operating Income | -188.97M |
| Pretax Income | -179.66M |
| Net Income | -179.53M |
| EBITDA | -171.84M |
| EBIT | -179.66M |
| Earnings Per Share (EPS) | -$1.66 |
Balance Sheet
The company has $141.08 million in cash and $18.34 million in debt, giving a net cash position of $122.74 million or $1.07 per share.
| Cash & Cash Equivalents | 141.08M |
| Total Debt | 18.34M |
| Net Cash | 122.74M |
| Net Cash Per Share | $1.07 |
| Equity / Book Value | 120.44M |
| Book Value Per Share | 1.05 |
| Working Capital | 133.83M |
Cash Flow
| Operating Cash Flow | -136.71M |
| Capital Expenditures | n/a |
| Free Cash Flow | -136.71M |
| FCF Per Share | -$1.19 |
Margins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
AlloVir does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -22.92% |
| Shareholder Yield | -22.92% |
| Earnings Yield | -200.14% |
| FCF Yield | -152.41% |
Analyst Forecast
The average price target for AlloVir is $5.88, which is 658.32% higher than the current price. The consensus rating is "Hold".
| Price Target | $5.88 |
| Price Target Difference | 658.32% |
| Analyst Consensus | Hold |
| Analyst Count | 5 |
| Revenue Growth Forecast (5Y) | n/a |
| EPS Growth Forecast (5Y) | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
| Altman Z-Score | n/a |
| Piotroski F-Score | 3 |